NASDAQ:ABUS
Arbutus Biopharma Corporation Stock News
$2.73
+0.0100 (+0.368%)
At Close: Apr 26, 2024
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
07:30am, Thursday, 18'th Apr 2024
WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fu
Moderna shares fall after judge sides with Arbutus in patent fight
02:02pm, Wednesday, 03'rd Apr 2024
Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus' arguments in a patent infringement lawsuit related to Moderna's blockbuster COVID-19 vaccines.
Arbutus to Participate in Two Upcoming Investor Conferences
07:30am, Friday, 08'th Mar 2024
WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fu
Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript
01:05pm, Thursday, 29'th Feb 2024
Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
09:41am, Thursday, 29'th Feb 2024
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago.
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
07:30am, Thursday, 15'th Feb 2024
WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fun
Arbutus to Present at Jefferies London Healthcare Conference
07:30am, Wednesday, 08'th Nov 2023
WARMINSTER, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensiv
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
07:30am, Tuesday, 24'th Oct 2023
WARMINSTER, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensiv
Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up
10:36am, Tuesday, 12'th Sep 2023
Arbutus (ABUS) makes a strategic decision to focus on the development of hepatitis B virus therapies while discontinuing all coronavirus and oral RNA destabilizer programs.
3 Stocks to Buy For the COVID Resurgence
08:44am, Thursday, 07'th Sep 2023
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting on updated COVID-19 vaccines at a meeting
Arbutus to Participate in Two Upcoming Investor Conferences
07:30am, Thursday, 07'th Sep 2023
WARMINSTER, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop nove
Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
10:31am, Thursday, 03'rd Aug 2023
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.10 per share a year ago.
Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update
07:30am, Thursday, 20'th Jul 2023
WARMINSTER, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel
Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
02:01am, Wednesday, 07'th Jun 2023
WARMINSTER, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel
Arbutus to Present at Jefferies Healthcare Conference
07:30am, Wednesday, 31'st May 2023
WARMINSTER, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive